Inhibitors of the sodium-glucose cotransporter 2 (SGLT2), initially developed as a treatment for individuals with type 2 diabetes, prevent reabsorption of filtered glucose and lower blood glucose levels by increasing urinary excretion.
1-3 In trials of participants with type 2 diabetes, these drugs led to a reduction in incident heart failure, which occurred early after randomization and appeared to be independent of baseline and time-dependent changes in glycated hemoglobin, suggesting this benefit may not necessarily be due to glucose lowering and might also be found in individuals without diabetes.
4-8 In parallel, experimental evidence emerged suggesting that SGLT2 inhibitors may have cardioprotective actions independent of blood glucose level.
9-11 The Dapagliflozin And Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial included patients with heart failure and reduced ejection fraction with and without type 2 diabetes. Dapagliflozin reduced the risk of worsening heart failure events and cardiovascular death and improved symptoms.
12,13 The key question arising from the DAPA-HF trial is how the effects of dapagliflozin compared in patients with and without diabetes, and whether the findings of this trial support the hypothesis that SGLT2 inhibition might be an effective treatment for patients with heart failure, including those without diabetes. In this exploratory analysis, the efficacy of dapagliflozin, along with metabolic and hemodynamic changes and adverse events, were analyzed in patients with heart failure with reduced ejection fraction with and without diabetes and across the range of baseline glycated hemoglobin levels in DAPA-HF.